Abstract
Background: Prediabetes is a metabolic condition characterized by blood sugar levels higher than normal but below the diabetic range. The onset of microvascular complications may set in this phase, hence intervening during the prediabetic stage becomes crucial in halting the progression to irreversible diabetes. We compared blood sugar levels between lifestyle modification and metformin medication and identified which option is better for managing prediabetes. Methods: A quasi-experimental study was done from January to October 2023 recruiting 150 prediabetic adults coming to Sikander Abad clinic through convenience sampling including 18 to 65 years of age while obese adults, those who had hypoglycemia within the past 3 months, and GDM women were excluded. Patients were divided into two groups and given a choice to choose pharmacotherapy (Metformin) or non-pharmacological measures (lifestyle modification). A thorough history and examination were done on all patients and Fasting Blood Sugar was done initially and after 3 months. SPSS version 21 was used. Independent and paired sample T-tests were used and chi-square was computed to see associations with the demographic factors. P-value <0.05 was considered significant. Results: Prediabetes was better controlled with Metformin (FBS-3.2mg/dl) as compared to lifestyle modification (FBS-2.7mg/dl) in our study (p<0.02). Non-obese patients constituted a higher proportion of the cohort, with 91(60%) compared to 59(39.3%) obese patients. Additionally, 43.3% of the study participants aimed to delay or prevent the onset and complications of Diabetes Mellitus. Conclusion: In our study, starting Metformin in the prediabetes phase, prevents or delays the progression to full-blown diabetes, contributing to a 0.5mg/dl reduction in glycemic control.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call